Pirtobrutinib, 99%

Name: Pirtobrutinib, 99% | 2101700-15-4
Brand: J&K Chemical
SKU: JK9336589_5_MG
Price: 27.7 USD
Availability: OutOfStock

Cat. No JK9336589_5_MG

Vendor: J&K Chemical

Product Information

Product Name

Pirtobrutinib, 99%

Brand Name

J&K

Product Number

9336589

CAS

2101700-15-4

Molecular Formula

C22H21F4N5O3

Molecular Weight

479.43

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

129269915

IUPAC Name

5-amino-3-4-(5-fluoro-2-methoxybenzoyl)aminomethylphenyl-1-(2S)-1,1,1-trifluoropropan-2-ylpyrazole-4-carboxamide

InChI Key

FWZAWAUZXYCBKZ-NSHDSACASA-N

SMILES

CC@@H(C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N

Safety Information

Storage Condition

Store at 2-8℃

References Data Source From Pubchem

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

Publication Name: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Publication Date: 2025-08

DOI: 10.1200/jco-25-00166

High‐Performance Liquid Chromatography–Ultraviolet Assay for the Determination of Pirtobrutinib Levels in a Patient With Mantle Cell Lymphoma

Publication Name: Biomedical chromatography : BMC

Publication Date: 2025-03-17

DOI: 10.1002/bmc.70061

Pirtobrutinib in Chinese patients with relapsed or refractory B‐cell malignancies: A single‐arm, open‐label, phase 2, multicenter trial

Publication Name: International Journal of Cancer

Publication Date: 2025-02-28

DOI: 10.1002/ijc.35339

Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies

Publication Name: Acta Haematologica

Publication Date: 2024-06-05

DOI: 10.1159/000539587

Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies

Publication Name: The Annals of pharmacotherapy

Publication Date: 2024-01-18

DOI: 10.1177/10600280231223737

Pirtobrutinib, 99%

Product Information

General Information

Safety Information

References Data Source From Pubchem

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

High‐Performance Liquid Chromatography–Ultraviolet Assay for the Determination of Pirtobrutinib Levels in a Patient With Mantle Cell Lymphoma

Pirtobrutinib in Chinese patients with relapsed or refractory B‐cell malignancies: A single‐arm, open‐label, phase 2, multicenter trial

Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies

Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies